OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Stefano Carugo, Cesare R. Sirtori, Guido Gelpi, et al.
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 11, pp. 805-817
Open Access | Times Cited: 12

Showing 12 citing articles:

Drug development advances in human genetics‐based targets
X. Zhang, Wenjun Yu, Yan Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 8

Differences in Stable and Unstable Atherosclerotic Plaque
Kenji Kawai, Rika Kawakami, Aloke V. Finn, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 7, pp. 1474-1484
Closed Access | Times Cited: 7

Lipid-lowering approaches to manage statin-intolerant patients
Massimiliano Ruscica, Alessandra Bertoletti, Cecilia Gobbi, et al.
European Heart Journal Supplements (2024) Vol. 26, Iss. Supplement_1, pp. i56-i59
Open Access | Times Cited: 4

Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Stephen J. Nicholls, Adam J. Nelson
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Closed Access

Advances in Pathological Mechanisms and Comprehensive Management of Hyperlipidemic Pancreatitis
柠 罗
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1975-1983
Closed Access

“INCLISIRAN: EARLY LDL-C TARGET ACHIEVEMENT IN A REAL-LIFE POPULATION”
Federica Briani, Mauro Bagli, Gabriele Venturi, et al.
Atherosclerosis Plus (2025)
Open Access

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
Alberto Corsini, Henry N. Ginsberg, M. John Chapman
Pharmacology & Therapeutics (2025), pp. 108812-108812
Closed Access

Lipoprotein(a) and the atherosclerotic burden – should we wait for clinical trial evidence before taking action?
Isabella Fichtner, Chiara Macchi, Alessandra Stefania Rizzuto, et al.
Atherosclerosis Plus (2024) Vol. 58, pp. 16-23
Open Access | Times Cited: 2

Management of Hypercholesterolemia in Patients with Coronary Artery Disease: A Glimpse into the Future
Alessandro Sciahbasi, Paola Russo, Michela Zuccanti, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7420-7420
Open Access | Times Cited: 1

The 10 essential questions regarding lipoprotein(a)
Karam Kostner, Gerhard M. Kostner
Current Opinion in Clinical Nutrition & Metabolic Care (2023) Vol. 27, Iss. 2, pp. 136-143
Closed Access | Times Cited: 2

Diseño y racional estudio observacional del Grupo Argentino Estudio Lipoproteína (a)
P. Corral, Augusto Lavalle Cobo, Matías Arrupe, et al.
Hipertensión y Riesgo Vascular (2024)
Closed Access

Page 1

Scroll to top